These therapeutic properties could further benefit from the ability of cetuximab-activated NK cells to induce an adaptive T-cell response against tumor antigens expressed by EGFR-positive cancer cells (52), which could boost the adaptive immune response to EGFR-expressing VR cells. This evidence concerns the gene EGFR and neoplasm.